SCHEMBL6427504

SCHEMBL6427504

Cc1c(C(C(=O)O)C2CCC2)c2cc(O)c(F)cc2n1C(=O)c1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
HTT P42858 1/20 0.38
EPHX2 P34913 1/20 0.37
PIK3CD O00329 1/20 0.37
LMNA P02545 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
GRM5 P41594 1/20 0.36
KMT2A Q03164 2/20 0.36
HSD11B1 P28845 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6425674 0.98 TDP1 (0.41) USP2TDP1KDM4ESMN1; SMN2HTT
SCHEMBL6423088 0.91 ALDH1A1 (0.37) KDM4EGRM5KMT2AHSD11B1ALDH1A1
SCHEMBL6426792 0.90 AKR1C3 (0.37) KDM4EEPHX2AKR1C3AKR1C2KMT2A
SCHEMBL6423706 0.89 L3MBTL1 (0.39) KDM4ELMNAKMT2AHSD11B1ALDH1A1
SCHEMBL6426037 0.89 MEN1 (0.37) LMNAAKR1C3AKR1C2GRM5KMT2A
SCHEMBL6425817 0.88 AKR1C3 (0.40) USP2TDP1KDM4ESMN1; SMN2HTT
SCHEMBL6424892 0.88 LMNA (0.34) HTTEPHX2LMNAAKR1C3AKR1C2
SCHEMBL6423904 0.88 AKR1C3 (0.37) KDM4ESMN1; SMN2EPHX2AKR1C3AKR1C2
SCHEMBL6424919 0.87 MEN1 (0.37) GRM5KMT2AHSD11B1MEN1CYP3A4
SCHEMBL6425963 0.86 PDE2A (0.35) AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 USP2 156/4885TDP1 3450/4885KDM4E 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.